Henry Schein (HSIC)
(Delayed Data from NSDQ)
$71.21 USD
-0.73 (-1.01%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $71.19 -0.02 (-0.03%) 7:58 PM ET
5-Strong Sell of 5 5
A Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$71.21 USD
-0.73 (-1.01%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $71.19 -0.02 (-0.03%) 7:58 PM ET
5-Strong Sell of 5 5
A Value B Growth D Momentum B VGM
Zacks News
AmerisourceBergen's (ABC) Venture Capital Fund to Aid Healthcare
by Zacks Equity Research
AmerisourceBergen's (ABC) new corporate venture capital fund to help emerging healthcare startup companies change healthcare for people and animals globally.
Here's Why You Should Retain West Pharmaceutical (WST) Now
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.
Henry Schein (HSIC) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Henry Schein (HSIC) owing to favorable dental business trends and a strong solvency position.
AmerisourceBergen (ABC) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about AmerisourceBergen's (ABC) strength in its World Courier business.
Here's Why You Should Invest In Henry Schein (HSIC) Now
by Zacks Equity Research
Investors are optimistic about Henry Schein (HSIC) owing to the favorable dental business trends.
PerkinElmer (PKI) Boosts In Vivo Imaging Profile With New System
by Zacks Equity Research
PerkinElmer's (PKI) launch of the Vega imaging system is likely to help the company expand its in vivo imaging portfolio.
PerkinElmer's (PKI) New Assay Kits to Detect CHO HCP Impurities
by Zacks Equity Research
PerkinElmer (PKI) launches ready-to-use HTRF and AlphaLISA no-wash assay kits to quickly identify and quantify CHO HCP impurities.
Catalent's (CTLT) Latest Buyout to Expand Its Global Footprint
by Zacks Equity Research
Catalent's (CTLT) latest acquisition is likely to significantly enhance its global Biologics business.
Baxter's (BAX) ST Set Receives FDA Nod, to Boost Patient Outcome
by Zacks Equity Research
Baxter's (BAX) ST Set is expected to improve treatments in an acute care environment.
Here's Why You Should Retain Cooper Companies (COO) Stock Now
by Zacks Equity Research
Cooper Companies (COO) continues to benefit from strength in its business segments.
Here's Why You Should Retain Merit Medical (MMSI) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.
Shockwave Medical's (SWAV) New Launch to Lower IVL Treatment Time
by Zacks Equity Research
Shockwave Medical's (SWAV) latest global commercial launch is expected to serve a more diverse patient pool.
DexCom's (DXCM) Upcoming Launch to Boost Diabetes Management
by Zacks Equity Research
DexCom's (DXCM) upcoming launch of Dexcom ONE CGM can help people in the U.K. to manage diabetes.
Here's Why You Should Hold on to Stryker (SYK) Stock for Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic-arm assisted surgery platform, Mako, and broad product portfolio. However, pricing pressure remains a concern.
Accuray's (ARAY) CyberKnife Effective for Relief From TN Pain
by Zacks Equity Research
Latest data indicates that Accuray's (ARAY) CyberKnife System is effective in providing long-lasting pain relief to patients suffering from TN.
Zimmer Biomet (ZBH) Hurt by China VBP, COVID-Led Staff Shortage
by Zacks Equity Research
Zimmer Biomet (ZBH) expects to face an adverse pricing impact in the first half of 2022, which is being compared to the non-VBP first half of 2021.
Here's Why You Should Retain AmerisourceBergen (ABC) Stock
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
NextGen (NXGN) Introduces New Integrated Care EHR Solution
by Zacks Equity Research
NextGen's (NXGN) newest solution lends support to comprehensive primary care and behavioral health with intellectual and developmental disabilities.
Here's Why You Should Add Bruker (BRKR) Stock to Your Kitty
by Zacks Equity Research
Bruker's (BRKR) Nano Group microelectronics and semiconductor metrology tools continue to perform well on ongoing strength in bookings and backlog.
3 Reasons to Retain Accuray (ARAY) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Accuray (ARAY) owing to its solid global reach.
Edwards Lifesciences (EW) Gets FDA Nod for MITRIS RESILIA Valve
by Zacks Equity Research
Edwards Lifesciences' (EW) MITRIS RESILIA valve has been designed to resemble the appearance and function of the native mitral valve.
Bio-Rad (BIO) Thrives on Global Sales and Testing Uptake
by Zacks Equity Research
Bio-Rad's (BIO) underlying Life Science business' core revenues grow on strong uptake of Droplet Digital PCR as well as the qPCR business.
Why Henry Schein (HSIC) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why You Should Retain Universal Health (UHS) Stock Now
by Zacks Equity Research
Increased admissions at both of its operating segments, constant initiatives to bolster its care network and adequate cash generation abilities are likely to drive Universal Health (UHS).
Cardinal Health (CAH) to Extend Medical Distribution Presence
by Zacks Equity Research
Cardinal Health's (CAH) plans to build a new facility in Columbus, OH, can expand its medical distribution footprint in the region.